PF-04950615

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Hypercholesterolemia

Phase 1

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

CompletedNCT01720537

PfizerHypercholesterolemia

Start: 2012-07-31End: 2013-10-31Updated: 2018-12-04

Phase 2

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

CompletedNCT01592240

PfizerHypercholesterolemia

Start: 2012-07-31End: 2013-05-31Updated: 2017-12-05

Related Papers

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.

2015-02-12135 citations